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The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor (KSHV/vGPCR) is a key molecule in the
pathogenesis of Kaposi's sarcoma. We have previously shown that 1α,25(OH)2D3 or its less-calcemic analog TX
527 inhibits the proliferation of endothelial cells expressing vGPCR, NF-κB activity and induces apoptosis in a
VDR dependent manner. In this work, we further explored whether 1α,25(OH)2D3 or TX 527 regulates PI3K/Akt/
mTOR axis and induces autophagy as part of its antineoplastic mechanism of action. Proliferation assays indicated
that vGPCR cell number decreased in presence of LY294002 (PI3K/Akt inhibitor) likewise 1α,25(OH)2D3 or TX
527 (10 nM, 48 h). Also, Akt phosphorylation was found decreased in dose (0.1–100 nM) and time response
studies (12–72 h) after both compounds treatments. In addition, decreased phosphorylated Akt was significantly
observed in the nucleus. Moreover, regulation of Akt phosphorylation was NF-κB and VDR dependent. TNFAIP3/
A20, an ubiquitin-editing enzyme, a direct NF-κB target gene and a negative regulator of Beclin-1, was down-
regulated whereas Beclin-1 was up-regulated after 10 nM of 1α,25(OH)2D3 or TX 527 treatment. Decrement in
Akt phosphorylation was accompanied by a reduced mTOR phosphorylation and an increase in the autophagy
marker LC3-II. Since increment in autophagosomes not always indicates increment in autophagy activity, we used
Chloroquine (CQ, 1 μM), an inhibitor of autophagy flow, to confirm autophagy after both VDR agonists treatment.
In conclusion, VDR agonists, 1α,25(OH)2D3 or TX 527, inhibited PI3K/Akt/mTOR axis and induced autophagy in
endothelial cells expressing vGPCR by a VDR-dependent mechanism.1. Introduction
Kaposi sarcoma-associated herpesvirus (KSHV, HHV-8) is a tumori-
genic γ-herpesvirus [1] and provokes the development of three human
malignancies. In endothelial cells, promotes Kaposi's sarcoma (KS) and in
B-cells, two lympho-proliferative diseases: primary effusion lymphoma
and the plasma cell variant of multicentric Castleman's disease [2]. These
diseases appear primarily in the context of immune deficiency and/or
HIV infection, though their pathogenesis differs [2]. KS is a multifocal,
highly vascular tumor; cells display features of activated endothelial
cells, and develops on the lower extremities, mucous membranes or in-
ternal organs [1, 3]. KSHV encodes several oncogenic viral homologues
of host proteins with the potential to stimulate cell survival, proliferation,
immune evasion and angiogenesis [4, 5, 6]. Among them, the viral G
protein-coupled receptor (vGPCR) has shown to transform endothelial
cells due to its pro-angiogenic capacity promoting tumor growth [3, 4, 5,lez-Pardo).
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is an open access article under t7]. The vGPCR is encoded by the ORF74, and presents homology with
CXCR1 and CXCR2, receptors of IL-8 and Gro-α in the host [3, 8, 9]. This
viral receptor is constitutively active because of the presence of structural
changes within its DRY domain in the second intra-cytoplasmic loop,
which is highly conserved in GPCRs [4, 10]. Among the multiple intra-
cellular pathways stimulated by vGPCR, the Akt/mTOR signaling axis
represents one of the most prominent oncogenicmechanism activated, an
event that has been revealed by animal models of KS [7, 11]. vGPCR
activates Akt/mTOR by stimulating PI3K through βγ-subunits and by an
autocrine manner up-regulating VEGFR2/KDR expression and VEGF
release [4, 12]. Moreover, PI3Kγ has been identified as the activator of
Akt/mTOR in endoth elial cells expressing vGPCR and also to mediate
sarcomagenesis in vivo [13].
It is well documented the important role of the PI3K/Akt pathway in
cell growth, proliferation, survival and metabolism [14]. In cancer cells,
it plays a central role in aerobic glycolytic reprogramming, tumorst 2019
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autophagy, is positively regulated by the PI3K/Akt pathway [16].
Autophagy is a mechanism that mediates the sequestration of cyto-
plasmic material in autophagosomes, double membrane vesicles, that in
turn fuse to lysosomes for degradation [17, 18]. Autophagy not only
occurs under normal conditions to maintain cell homeostasis, but also
during unfavorable conditions [16, 19]. In neoplastic cells, autophagy
constitutes a mean to face intracellular and environmental stress, thus
favoring tumor progression [18]. There are several autophagy inducers
that operate in general activating cascades of signal transduction that
result in mTOR complex 1 inhibition [20, 21]. Among other effects, this
allows the activation of proteins that are crucial in autophagosomes
formation, such as ULK-1, ATG13 and Beclin-1 (BECN1) [18,22]. Auto-
phagy is governed by a series of Atg genes [16, 18, 23]. Although all
ATG8 proteins are indispensable for autophagy, LC3 acts as the major
ATG8 protein to induce autophagy; thus, increased levels of LC3-II pro-
teins in autophagosome membranes are important biomarkers of auto-
phagy [16, 24].
The active form of vitamin D, 1α, 25 (OH)2-vitamin D3
(1α,25(OH)2D3) or calcitriol plays an important role in maintaining
calcium homeostasis. Most of 1α,25(OH)2D3 actions are mediated
through the vitamin D receptor (VDR), a member of the nuclear receptor
superfamily [25]. In addition to its classical effects, 1α,25(OH)2D3 has
antineoplastic and anti-inflammatory effects in several tumor types. The
anti-proliferative, pro-apoptotic and pro-differentiation action of the
metabolite has been demonstrated in various malignant cells and also in
animal models where it retards tumor growth [26, 27, 28, 29, 30, 31]. We
have previously revealed that 1α,25(OH)2D3 or its less-calcemic analog
TX 527 inhibits the proliferation of endothelial cells expressing vGPCR in
vitro and in vivo [32], down regulates NF-ĸB pathway, highly activated by
the viral receptor [33, 34], and induces apoptosis in a VDR dependent
manner [35, 36]. Since there is evidence indicating that 1α,25(OH)2D3
triggers autophagy as part of its mechanism of action in certain tumor
cells [37, 38, 39], we further explore whether 1α,25(OH)2D3 or TX 527
induces autophagy in endothelial cells expressing vGPCR by inhibiting
PI3K/Akt/mTOR pathway.
2. Materials and methods
2.1. Materials
Vitamin D analog TX 527 [19-nor-14,20-bisepi-23-yne-1,25(OH)2D3]
was originally synthesizedbyM.Vandewalle andP.De Clercq (University of
Ghent, Ghent, Belgium) and provided by Theramex (Monaco). Immobilon P
(polyvinylidenedifluoride; PVDF)membranes, 1α,25(OH)2D3, theantibiotic
G418 and LY294002 were from Sigma-Aldrich (St. Louis, MO, USA). Puro-
mycin supplied by Invivogen (San Diego, CA, USA). The antibodies used
were rabbit monoclonal anti-p-Akt, anti-Akt, anti-MEKα (Cell Signaling
Technology, Danvers, MA, USA) and anti-Tubulin (Thermo Fisher Scientific
Inc., Waltham, MA, USA); mouse monoclonal anti-LC3, anti-BECN1, anti-p-
mTOR, and anti-mTOR, goat polyclonal Lamin B and secondary antibodies
anti-rabbit,anti-mouseandanti-goat (SantaCruzBiotechnology,SantaCruz,
CA, USA). Roche Applied Science supplied high Pure RNA Isolation Kit
(Indianapolis, IN, USA). High Capacity cDNA RT and SYBR Green PCR
MasterMix reagent (Applied Biosystems) were acquired from Thermofisher
(Thermofisher, Buenos Aires, AR). GAPDH primer was from InvitrogenTM
(Invitrogen/Thermo Fisher Scientific Inc., Waltham, MA, USA) and BECN1
primer was obtained by Eurogentec (Serain, Belgium). The inhibitor of flux
autophagy, Chloroquine,was kindly providedbyDr. DanielGrasso (IBIMOL
Universidad de Buenos Aires – CONICET).
2.2. Cell lines and transfections
SV-40 immortalized murine endothelial cells (SVEC) stably express-
ing the vGPCR (full-length) were used as experimental model of KS [3,
32]. Cells were cultured and selected with 500 μg mL1 G418 [3]. Stable2
vGPCR endothelial cells targeted with small hairpin RNA against mouse
VDR (vGPCR-shVDR) or control shRNA (vGPCR-shctrl) were obtained
before by transduction of lentiviral particles generated in HEK293T cells
and selected with 2 μg mL1 puromycin [32].
2.3. Proliferation assays
vGPCR cells were seeded in 24-well plates, at 6000 cells per well.
After overnight growth, the cells were starved for 24 h and then treated
with 10 nM of 1α,25(OH)2D3 or TX 527 or vehicle (0.01%, ethanol) in
triplicate in DMEM 2% fetal bovine serum (FBS) for 48 h. Cells were then
harvested and counted in a Neubauer chamber using 0,4% of trypan blue
stain to distinguish living from died cells according to trypan blue
exclusion test [40] In addition, proliferation was measured using Cell-
Titer 96® AQueous one solution cell proliferation assay containing 3-(4,
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophe-
nyl)-2H-tetrazolium, inner salt (MTS) in 96-well plates as we have pre-
viously reported [34].
2.4. SDS-PAGE and Western blot
Whole protein lysates were prepared as previously reported by us
[33] and protein content was determined by the Bradford procedure
[41]. Proteins were resolved (with SDS–PAGE) and transferred to PVDF
membranes followed by Western blot analyzes [41]. Membranes were
blocked and incubated with primary antibodies [anti: p-Akt (1:1000),
Akt (1:1000), Tubulin (1:1000), MEKα (1:1000), Lamin B (1:1000),
BECN1 (1:500), LC3 (1:500), p-mTOR (1:500), mTOR (1:500)] diluted in
TBST buffer (0.1% tween) overnight at 4 C. After three washes in TBST
buffer, membranes were incubated with the corresponding secondary
antibodies (1:5000) diluted in TBST buffer (2.5% dry milk) 1 h at room
temperature. Later, after three washes in TBST buffer, blot signal was
detected using an enhanced chemiluminescence kit according to the
manufacturer's instructions (Amersham ECL Western Blotting Detection
Kit, GE Healthcare, Buenos Aires, AR). Images were scanned and quan-
tified using ImageJ software, developed at the National Institutes of
Health.
2.5. Subcellular fractionation
vGPCR cells were scrapped in ice-cold Tris-EDTA-Sucrose (TES)
buffer (50 mmol L1Tris-HCl pH 7.4, 1 mmol L1 EDTA, 250 mmol L1
sucrose, 1 mmol L1 DTT) containing proteases inhibitors (0.5 mmol L1
PMSF, 20 μg mL1 aprotinin and 20 μg mL1 leupeptin). Lysates were
passed through a 25 G needle 10 times using a 1 mL syringe and left on
ice for 20 min. Then, homogenate was centrifuged at 100 g for 5 min to
eliminate debris; supernatant was further centrifuged at 1500 g for 20
min to sediment the nuclear fraction. The supernatant was further
centrifuged at 14000 g for 20 min to pellet mitochondria. The remaining
supernatant was collected as cytosol fraction [42]. Protein concentration
from each fraction was estimated by the Bradford method. Goat
anti-Lamin B and rabbit anti-MEKα antibodies were employed for the
immunodetection of the nuclear protein marker Lamin B and the cytosol
protein marker MEKα, in the different fractions.
2.6. Quantitative real-time PCR
Total RNA for real-time quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR) analysis was isolated using the High Pure RNA
Isolation Kit (Roche) [34]. Total RNA (1 μg) was reverse transcribed using
the kit High Capacity cDNA RT (Applied Biosystems, Thermofisher, Buenos
Aires, AR) and qRT-PCR reactions were achieved on the resulting cDNA
(5–10 ng) in an ABI 7500 Real Time PCR system (Applied Biosystems, CA,
USA) using specific primers to detect A20 and BECN1 levels and GAPDH to
normalize gene expression. Primers used for amplification were: murine
Gapdh, forward 50-AAGGTGAAGGTCGGAGTC-30, reverse
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50-GGACAAGCTCAAGAAAACCAATG-30, reverse 50-TGTCCGCTGTGCCA-
GATG-3’; murine A20 forward 50-CATGAAGCAAGAAGAACGGAAGA-30,
reverse 50-GAGGCCCGGGCACATT-3’. Reactions were carried out using the
SYBRGreenPCRMasterMix reagent (AppliedBiosystems).Gene expression
was then analyzed by 2-delta delta Ct method [43].
2.7. Statistical analysis
Data are shown as means aSD. Data from control and treated con-
ditions obtained by qRT-PCR or Western blot were analyzed by the two
tailed t-test. A p value <0.01 (**) and <0.05 (*) were considered sta-
tistically significant. Data from more than two conditions were analyzed
by one-way ANOVA followed by Bonferroni test. Different superscript
letters indicate significant differences at p < 0.05 or p < 0.01.
3. Results
3.1. Akt inactivation reduces vGPCR cell number likewise 1α,25(OH)2D3
or TX 527
In a cellular model of KS, Martin and colleagues reported that vGPCRFig. 1. vGPCR cell growth inhibition by LY294002 and VDR agonists. vGPCR cells we
(0.01% ethanol) or 10 μM of LY294002 (LY) for 48 h. A) Representative micrographs
were counted in Neubauer chamber or C) in parallel experiments, MTS assay was
presented in bar graphs. The statistical analysis was performed by one-way ANOVA f
letters (p < 0.01).
3
expression in endothelial cells strongly stimulates Akt (pAkt S473) and
mTOR, event that was accompanied by morphological changes with an
increase in cell size and a longer survival of cells after growth factors
deprivation [44]. We first investigated whether 1α,25(OH)2D3 or TX 527
exerts its anti-proliferative effect through the regulation of Akt in endo-
thelial cells transformed by vGPCR. To that end, vGPCR cells were treated
with 10 nM of 1α,25(OH)2D3 or TX 527 or 10 μM of LY294002 (PI3K/Akt
inhibitor) or vehicle (0.01% ethanol) for 48 h. After treatment, micrographs
of each condition were taken in a phase contrast microscope (Fig. 1A). To
measure cell proliferation, cells were collected, counted in a Neubauer
chamber and, finally, living cells percentage was calculated according to
control cells (Fig. 1B). As can be seen from Fig. 1, vGPCR cells number
decreased significantly in presence of LY294002 similar to 1α,25(OH)2D3
or TX 527. Furthermore, these results were confirmed by the 3-(4,
5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay (Fig. 1C). In
addition, these effects were accompanied by cellular morphological
changes, observed by light field microscopy showed abnormal round cells
and condensed nuclei, presuming that Akt inhibition is part of both com-
pounds antineoplastic action. To evaluate this possibility, Akt phosphory-
lation state was studied as a measure of its activity in dose and time
response studies. vGPCR cells were treated with increasing concentrationsre seeded and treated with 10 nM of 1α,25(OH)2D3 (1,25D) or TX 527 or vehicle
obtained by phase contrast microscopy, bar: 30 μm, magnification 200x. B) Cells
performed, and the results, from at least three independent experiments, were
ollowed by the Bonferroni test. Significant differences are indicated by different
A. Suares et al. Heliyon 5 (2019) e02367of 1α,25(OH)2D3 or TX 527 (0.1–100 nM) or vehicle (0.01% ethanol) for 48
h or with 10 nM of each compound for different times (12–72 h). Then, Akt
protein levels and its phosphorylation state were analyzed by Western blot.
The results presented in Fig. 2A show that both compounds caused a sig-
nificant decrease in Akt phosphorylation without modifying its total pro-
tein levels in a dose-dependent manner. In addition, time-response studies
revealed that Akt phosphorylation significantly decreased after 12–72 h of
1α,25(OH)2D3 or TX 527 treatment (Fig. 2B).Fig. 2. 1α,25(OH)2D3 or TX 527 decreases Akt phosphorylation in a dose and time de
1α,25(OH)2D3 (1,25D) or TX 527 (0–100 nM), or vehicle (0.01% ethanol) for 48 h or B
h). Total and phosphorylated Akt was analyzed by Western blot and Tubulin was used
experiments and their quantification in bar graphs are shown. The statistical analy
Different letters indicate significant differences between conditions with p < 0.01; an
at each time point by the Student's t test (*p < 0.05; **p < 0.01). Full, non-adjuste
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3.2. 1α,25(OH)2D3 inhibits the translocation of phosphorylated Akt to the
nucleus
To inquire into 1α,25(OH)2D3 mechanism of action on Akt regulation,
we next investigated whether the observed decrease in Akt phosphory-
lation affects its subcellular location. For this, vGPCR cells were treated
with 10 nM of 1α,25(OH)2D3 or vehicle (0.01% ethanol) for 48 h. Then,
cells were collected, homogenized in TES buffer and a subcellularpendent manner. vGPCR cells were treated with A) increasing concentrations of
) 10 nM of 1,25D or TX 527 or vehicle (0.01% ethanol) at different times (12–72
as loading control. In A and B a representative blots of at least three independent
sis in A was performed by one-way ANOVA followed by the Bonferroni test.
d in B the effect of each treatment (1,25D or TX 527) was compared with control
d and uncropped images of Fig. 2 are shown in suppl. material.
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Phosphorylated and total Akt levels were analyzed by Western blot and
the purity of the fractions was determined through specific markers,
Lamin B for nucleus and MEKα for cytosol. The results in Fig. 3 indicate
that 1α,25(OH)2D3 provoked a significant decrease in phosphorylated
Akt in the nucleus respect to cytosol (Fig. 3B) suggesting the attenuation
of Akt activity in the nucleus due to 1α,25(OH)2D3 treatment and its
translocation to cytosol (Fig. 3C).3.3. 1α,25(OH)2D3 or TX 527 decreases Akt activation by a VDR
dependent mechanism
Like other steroid hormones, 1α,25(OH)2D3 exerts its effect through a
genomic mechanism mediated by VDR and a non-genomic one of rapid
responses initiated in the membrane [45]. Therefore, we investigated
whether VDR knockdown affects Akt activation. We used the
vGPCR-shVDR cell line where VDR expression was silenced by a short
hairpin against mouse VDR, or the control line, vGPCR-shctrl. Both cell
lines were treated with 10 nM of 1α,25(OH)2D3 or TX 527 or vehicle
(0.01% ethanol) for 48 h (Fig. 4A). First, VDR knockdown was verified as
we have reported before (Suppl. Material) (Gonzalez Pardo et al., 2010,
Gonzalez Pardo et al 2014). Second, as it was previously observed, 1α,
25(OH)2D3 or TX 527 significantly decreased Akt phosphorylation afterFig. 3. Subcellular localization of Akt by 1α,25(OH)2D3. vGPCR cells were cultured a
48 h. Then, cells were collected in TES buffer and a subcellular fractionation was p
phosphorylated and total Akt and specific markers for each fraction, MEKα for C an
independent experiments are shown and their quantification is represented in a bar
Statistical analysis was performed by the Student's t-test, significant differences betw
uncropped images of Fig. 3 are shown in suppl. material.
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48 h of treatment, whereas when VDR expression was knockdown, Akt
phosphorylation was not affected by both agonists.
3.4. Inhibition of NF-ĸB pathway by Bortezomib decreases Akt
phosphorylation like VDR agonists
Results from our group have revealed that the inhibition of the NF-ĸB
pathway by Bortezomib plays an important role in the regulation of the
cell cycle [34]. This regulation could be attributed to an inhibition of Akt
activity by NF-κB. To evaluate this possibility, vGPCR cells were treated
with increasing concentrations of Bortezomib (0.25–1 nM) or vehicle
(0.1% DMSO) for 24 h and then Akt phosphorylation state was assessed
byWestern blot. The results presented in Fig. 4B indicate that Bortezomib
induced a significant decrease of Akt phosphorylation in a
dose-dependent manner; however, at the highest concentration of 1 nM,
Akt phosphorylation tended to increase, suggesting that activated Akt
contribute to activate cell survival and counteract the apoptosis induced
by Bortezomib.
3.5. A20 is highly expressed in vGPCR cells and is down-regulated by
1α,25(OH)2D3 or TX 527
TNFAIP3/A20 is an ubiquitin-editing enzyme and a direct NF-κBnd treated with 10 nM of 1α,25(OH)2D3 (1,25D) or vehicle (0.01% ethanol) for
erformed to obtain the nuclear fraction (N) and the cytosol (C). The levels of
d Lamin B for N, were analyzed by Western blot. Representative blots of three
graph where the radio of p-Akt/Total is expressed in N with respect to C (N: C).
een the 1,25D and control were evaluated (*p < 0.05). Full, non-adjusted and
Fig. 4. Decreased Akt phosphorylation is VDR and NF-ĸB dependent. A) vGPCR-shctrl (shctrl) and vGPCR-shVDR (shVDR) cells were cultured and treated with 10 nM
of 1α,25(OH)2D3 (1,25D) or TX 527 or vehicle (0.01% ethanol) for 48 h. B) vGPCR cells were treated with Bortezomib (0.25–1 nM) or vehicle (DMSO, 0.1%) for 24 h.
Phosphorylated and total Akt levels were evaluated by Western blot and Tubulin was used as loading control. Representative blots of at least three independent
experiments and their quantification plotted on a bar graph are shown. Full, non-adjusted and uncropped images and VDR silencing are shown in suppl. material. The
statistical differences were analyzed by one-way ANOVA followed by the Bonferroni test. Different letters indicate significant differences (p < 0.05).
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some cell lines [46]. It has been proposed that A20 expression limits
TLR4-induced autophagy by deubiquitinating TRAF6 and BECN1 [47]. In
earlier studies, we have demonstrated that NF-κB is highly expressed in
vGPCR cells and is down regulated by VDR agonists [33, 34]. Here, we
investigated A20 expression in SVEC and vGPCR cells and whether it was
regulated by NF-κB inhibitor Bortezomib or VDR agonists as part of their
mechanism of action (Fig. 5). First, SVEC and vGPCR cells were cultured
and treated with Bortezomib at different concentrations or vehicle
(DMSO, 0.1%) during 24 h and then A20 protein levels were analyzed by
Western blot. According to Fig. 5A, A20 was barely expressed in SVEC
cells whereas was found highly expressed in vGPCR and down-regulated
by Bortezomib in a dose-response manner. Secondly, dose (0.1–100 nM)
(Fig. 6) and time response studies (10 nM, 3–72 h) were carried out to
investigate the role of 1α,25(OH)2D3 or TX 527 on A20 expression
(Fig. 5B and C). The results of these studies indicated that both com-
pounds decreased A20 protein expression in dose and time studies,
though the effect was reverted at 100 nM of both compounds. Moreover,
A20 mRNA was rapidly decreased at 3 h and sustained up to 72 h
(Fig. 5B); response that was reflected in a decrement in A20 protein
expression (12–72 h) analyzed byWestern blot (Fig. 5C). In addition, this
effect was found to be VDR dependent (Fig. 7).
3.6. 1α,25(OH)2D3 or TX 527 induces changes in BECN1 expression
BECN1 is a protein that is expressed in many human tissues and there
is evidence suggesting that the transcription factor E2F and NF-κB are
involved in the regulation of its expression [48]. Wang and colleagues
demonstrated that 1α,25(OH)2D3 induces autophagy in human myeloid
leukemia cells by up-regulation of BECN1 expression and inhibition of
mTOR phosphorylation [37]. We next evaluated whether BECN1 is
regulated by both VDR agonists. First, vGPCR cells were treated with 10
nM of 1α,25(OH)2D3 or TX 527 or vehicle (0.01% ethanol) at different6
times (Fig. 8). BECN1 mRNA levels were analyzed in time-response
studies (6–48 h) by qRT-PCR (Fig. 8A). Treatment with 1α,25(OH)2D3
caused a significant decrease in BECN1 mRNA levels at 12 and 24 h,
whereas at 48 h, a highly significant increase was observed. In contrast,
TX 527 caused a significant increase in BECN1 mRNA levels at 12 and 24
h, and a highly significant decrease at 48 h. Secondly; we investigated
whether changes in BECN1mRNA expressionwere reflected into changes
in its protein levels in parallel experiments (Fig. 8B). The quantification
of the results obtained reveal that 1α,25(OH)2D3 induced a significant
increase in BECN1 protein levels at 24 h and a decrease at 12 and 48 h;
meanwhile, TX 527 induced a significant increase in BECN1 in a time
dependent manner between 12 to 48 h. Discrepancies observed between
transcript and protein levels at same time point could be related with
regulatory mechanisms occurring after mRNA is synthetized and protein
abundance regulation.
3.7. 1α,25(OH)2D3 or TX 527 inhibits mTOR phosphorylation and
induces autophagy by a PI3K/Akt dependent mechanism
As outlined in the introduction, autophagy is governed by a series of
Atg genes, being LC3 an important biomarker of autophagy. During the
process of autophagosome development, ATG8 proteins are specifically
cleaved to expose a glycine residue to become ‘form I’ proteins, then, this
glycine residue is then conjugated to phosphatidylethanolamine,
changing into ‘form II’ proteins [23]. Fleet and collaborators reported
that 1α,25(OH)2D3 suppresses mTOR in leukemia cells contributing to
the development of autophagy [49]. Next, mTOR phosphorylation status
was evaluated as a measure of its activity and LC3-II proteins levels as a
measure of autophagy. vGPCR cells were treated with 10 nM of 1α,
25(OH)2D3 or TX 527 or vehicle (0.01% ethanol) for 48 h (Fig. 9A). To
evaluate the participation of the PI3K/Akt/mTOR axis in autophagy
triggered by 1α,25(OH)2D3, vGPCR cells were incubated with 10 μM of
LY294002 or vehicle (0.01% ethanol) during 15 min prior to 1α,
Fig. 5. A20 is regulated by Bortezomib and VDR agonists in vGPCR cells. A) SVEC and vGPCR cells were treated with Bortezomib (0.25–1 nM) or vehicle (DMSO,
0.1%) for 24 h A20 protein levels were tested by Western blot and Tubulin was used as loading control. Representative blots of at least three independent experiments
and their quantification plotted on a bar graph are shown. The statistical differences were analyzed by one-way ANOVA followed by the Bonferroni test. Different
letters indicate significant differences (p < 0.05). vGPCR cells were treated with 10 nM of 1α,25(OH)2D3 (1,25D) or TX 527 or vehicle (0.01% ethanol) at different
times to evaluate A20 gene (3–72 h) and protein (12–72 h) expression. B) Total RNA was isolated and A20 expression was evaluated on the resulting cDNA and the
values obtained were normalized with GAPDH as shown in the bar graph. C) Protein levels of A20 and Tubulin were analyzed by Western blot. Representative blots
and their quantification of at least three independent experiments are shown in a bar graph. Significant differences between 1,25D or TX527 and their respective
control at each time were analyzed by the Student's t test (*p < 0.05, **p < 0.01). Full, non-adjusted and uncropped images are shown in suppl. Material.
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(Fig. 9B). The results shown in Fig. 9A indicate that 1α,25(OH)2D3 or TX
527 decreased mTOR phosphorylation without causing changes in its
total protein levels. In addition, autophagy was induced by 1α,
25(OH)2D3 (Fig. 9B) and in presence of LY294002, LC3-II levels were
significant increased comparable to 1α,25(OH)2D3 treatment. Moreover,
LC3-II levels showed no greater increase when LY294002 was combined
with 1α,25(OH)2D3.
3.8. Inhibition of autophagy flow with Chloroquine induces LC3 proteins
levels like VDR agonists
Because the accumulation of autophagosomes is toxic to cells [50,7
51], the blockage of autophagosomes degradation with Chloroquine after
1α,25(OH)2D3 or TX 527 treatment could be detrimental to vGPCR cells
survival and this would allow us to confirm autophagy induction. To test
this hypothesis, vGPCR cells were treated with 10 nM of 1α,25(OH)2D3 or
TX 527 or vehicle (0.01% of ethanol) for 48 h and 30 min prior to finish
VDR agonists treatments, Chloroquine (1 μM, CQ) was added to inhibit
autophagy flow by decreasing the autophagosome-lysosome fusion [52,
53, 54]. In presence of CQ, LC3-II levels were comparable to control
condition and in combination with 1α,25(OH)2D3 did not increase,
whereas with TX 527 the effect observed was enhanced (Fig. 10A). We
also investigated whether VDR participates in LC3-II induction by both
VDR agonists. For this, vGPCR-shVDR or vGPCR-shctrl cells were treated
with 10 nM of 1α,25(OH)2D3 or TX 527 or vehicle (0.01% ethanol) for 48
Fig. 6. 1α,25(OH)2D3 or TX 527 decreased A20 protein levels in a dose dependent manner in vGPCR cells. vGPCR cells were treated with increasing concentrations of
1α,25(OH)2D3 or TX 527 (0–100 nM) or vehicle (0.01 % ethanol) for 48 h. Cell lysates were subject to Western blot analysis with anti-A20 and anti-Tubulin antibodies.
Representative blots and quantification of at least three independent experiments are shown. Full, non-adjusted and uncropped images are shown in suppl. Material.
Protein bands quantification were achieved by densitometry and then represented in bar graphs as the radio between A20 and Tubulin referred to vehicle. The
statistical analysis of the results was carried out by one way-ANOVA followed by Bonferroni test. Different letters indicate statistical significances at *p < 0.01.
A. Suares et al. Heliyon 5 (2019) e02367h (Fig. 10B). The results showed that the significant increase in LC3-II
amount was suppressed when VDR expression was knockdown8
indicating that both, 1α,25(OH)2D3 and TX 527, exert their actions
through a VDR dependent mechanism of action.Fig. 7. A20 downregulation by VDR agonists is VDR
dependent. Stable vGPCR cells targeted with small hairpin
RNA against mouse VDR (vGPCR-shVDR) or control (vGPCR-
shctrl) were treated with 10 nM of 1α,25(OH)2D3 or TX 527
or vehicle (0.01% ethanol) for 48 h. Total protein from cells
lysates were subject to Western blot analysis with anti-A20
and anti-Tubulin antibodies. A representative Western blot
from four independent experiments is shown; full, non-
adjusted and uncropped images are shown in suppl. Mate-
rial. A20 protein bands were quantified, normalized using
Tubulin, and represented in a bar graph. Significant differ-
ences between control (vehicle) and stimulated cells were
analyzed by one-way ANOVA followed by Bonferroni test, p
< 0.01.
Fig. 8. 1α,25(OH)2D3 or TX 527 induces changes in BECN1 expression. vGPCR cells were treated with 10 nM of 1α,25(OH)2D3 (1,25D) or TX 527 or vehicle (0.01%
ethanol) for different times to evaluate BECN1 gene (6–48 h) and protein (6–72 h) expression. A) Total RNA was isolated and BECN1 expression was evaluated on the
resulting cDNA and the values obtained were normalized with GAPDH as shown in the bar graph. B) Protein levels of BECN1 and Tubulin were analyzed by Western
blot. Representative blots and their quantification of at least three independent experiments are shown in a bar graph; full, non-adjusted and uncropped images are
shown in suppl. Material. Significant differences between 1,25D or TX527 and their respective control at each time were analyzed by Student's t test (*p < 0.05, **p
< 0.01).
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Apoptosis and autophagy are evolutionarily conserved processes that
regulate cell fate. Both processes are important for the development and
normal physiology of tissues and have been found to be regulated in a
wide range of diseases [55]. It is well known that infection with KSHV
induces the expression of viral proteins that contribute to the develop-
ment of different malignancies. It has been observed that vFLIP, for
example, suppresses apoptosis and autophagy favoring cell survival. On
the other hand, infection with KSHV activates mTOR, a negative regu-
lator of autophagy process and an important molecule for cell prolifer-
ation, modulation and angiogenesis [5]. Autophagy is induced by several
forms of cellular stress including starvation, hypoxia and infection, as
well as can be induced by drugs used in therapy against cancer and other
diseases [44, 56]. Numerous studies have shown that 1α,25(OH)2D3 has
the ability to induce autophagy in different cell types. For instance, in
lymphoma cells and breast cancer, 1α,25(OH)2D3 and its analog EB1089
showed a cytotoxic effect triggering cell death by a caspase independent
mechanism, characterized by an increase in lysosomal activity [38]. In
addition, 1α,25(OH)2D3 has shown to induce autophagy in myeloid
leukemia and in luminal breast cancer cells [37, 39]. Also, 1α,
25(OH)2D3-induced autophagy may require a complex interplay with
CDK inhibitors, for instance, in p19 deficient SCC25 cells 1α,25(OH)2D39
autophagy induction can be suppressed by p27 suppression [57]. More-
over, studies in breast cancer cells revealed that the combined treatment
of 1α,25(OH)2D3 plus ionizing radiation induces cytotoxic autophagy
[58]. This effect of 1α,25(OH)2D3 is not limited to cancer cells. In this
regard, concentrations at picomolar order of the metabolite have shown
to induce autophagy in primary monocytes and macrophages suggesting
that it could stimulate autophagy in normal physiological conditions
[59]. 1α,25(OH)2D3 may prevent human umbilical vein endothelial cells
death through modulation of the interplay between apoptosis and auto-
phagy. This effect is obtained by inhibiting superoxide anion generation,
maintaining mitochondria function and cell viability, activating survival
kinases, and inducing nitric oxide production [60]. In this work, we have
obtained evidence indicating that inhibition of PI3K/Akt pathway causes
a decrease in cell proliferation comparable to VDR agonists in vGPCR
cells. As previously mentioned, Akt plays a crucial role in the develop-
ment of KS [7, 11]. Moreover, we found that both VDR agonists reduce
Akt phosphorylation state through a VDR dependent mechanism and
decreases its translocation to the nucleus. In support of these results,
recent findings in vitro and in vivo studies in breast cancer models showed
an active role of 1α,25(OH)2D3 in the induction of autophagy by a
mechanism that involves VDR participation [39]. Wu and colleagues
demonstrated that the absence of intestinal epithelial VDR affects mi-
crobial assemblage and increases susceptibility to dextran sulfate
Fig. 9. 1α,25(OH)2D3 or TX 527 decreases mTOR phosphorylation and induces autophagy. vGPCR cells were incubated with 10 μM of LY294002 (LY) or vehicle
(0.01% ethanol) for 15 min prior to 1α,25(OH)2D3 (10 nM) or vehicle (0.01% ethanol). The protein levels of phosphorylated and total mTOR (A) or LC3 (B) were
analyzed by Western blot using Tubulin as loading control. Representative blots are shown and the quantification of six independent experiments is represented in bar
graphs. Significant differences between conditions were evaluated in A) by one-way ANOVA followed by the Bonferroni test (p < 0.05) or B) significant differences
between pairs of conditions were evaluated through the Student t test (*p < 0.05, **p < 0.01, n. s: not significant). Full, non-adjusted and uncropped images are shown
in suppl. Material.
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zyme expression, and impairs antimicrobial function and autophagy of
Paneth cells [61]. Similar to VDR agonists, Bortezomib caused a decrease
in Akt phosphorylation in a dose-dependent manner. In support of this
result, studies in different hepatocarcinoma cell lines showed that Bor-
tezomib decreases Akt phosphorylation/activation preceding cell death
by apoptosis [62]. Furthermore, in SK-BR-3 cells, a marked inhibition of
EGFR, HER-2, and Akt phosphorylation was observed at a clinically
relevant concentration of Bortezomib [63]. In this work, we have also
obtained evidence that 1α,25(OH)2D3 or TX 527 decreased mTOR
phosphorylation and induced autophagy revealed by an increment in
LC3-II marker, an event that is triggered by inactivation of PI3K/Akt
pathway. In agreement with this result, in vivo studies showed that
treatment with Hesperidin attenuates myocardial lesions caused by
ischemia/reperfusion by suppressing autophagy through activation of
the PI3K/Akt/mTOR pathway [64]. Also, Yang and collaborators pre-
sented data suggesting that the protective role of vitamin D in mouse
liver ischemia/reperfusion injury is autophagy-dependent, which is
regulated by both MEK/ERK and PTEN/PI3K/Akt/mTOR pathway [65].
Many autophagy regulators are substrates for ubiquitin E3 ligases or
deubiquitinating enzymes, therefore ubiquitination modifications of
these autophagy regulators result in autophagy induction or termination
[66]. As was mentioned before, TNFAIP3/A20 is a direct NF-κB target
gene, and A20 expression could limit autophagy by regulating BECN1.
We have found that A20 is highly expressed in vGPCR and its expression
is down-regulated by the inhibition of NF-κB with Bortezomib or VDR10agonists in a VDR dependent manner. We have also found that BECN1 is
temporarily modulated by VDR agonists. Although BECN1 mRNA and
protein levels vary, when it is increased, it would regulate the initial steps
of autophagy. Autophagy and apoptosis can be trigger by common
stimuli and signaling pathways leading to a balance between both pro-
cesses. It has been described that BECN1 is involved in these processes.
On one hand, BECN1 participates in autophagosome formation upon
autophagy stimuli, on the other, it can be cleaved by caspases, translocate
to the mitochondria, and participate in apoptosis induction [48]. We
have shown in previous studies that apoptosis is induced by VDR agonists
by a caspase-3 dependent mechanism in vGPCR cells [35], so that, the
differences observed in BECN1 levels could be explained by the fact that
this protein could cooperate in both processes to contribute to cell death.
In support of our results, BECN1has shown to participate in the activation
of apoptosis and autophagy pathways induced by EB1089, a synthetic
analog of 1α,25(OH)2D3, in breast cancer cells (MCF-7) [67]. On the
other hand, an increase in BECN1 levels, triggers differentiation, inhibits
apoptosis and induces autophagy in myeloid leukemia cells after 1α,
25(OH)2D3 treatment [37].
5. Conclusions
Taken together, these results demonstrate that 1α,25(OH)2D3 or TX
527 induces autophagy in endothelial cells expressing vGPCR through
the inactivation of PI3K/Akt/mTOR axis by a VDR-dependent
mechanism.
Fig. 10. Inhibition of autophagy flow with Chloroquine induces LC3 levels and is VDR dependent. A) Cells were treated with 10 nM of 1α,25(OH)2D3 (1,25D) or TX
527 or vehicle (0.01% of ethanol) for 48 h and 30 min before the end of VDR agonists treatments, 1 μM of Chloroquine (CQ) was added. B) vGPCR-shctrl (shctrl) and
vGPCR-shVDR (shVDR) cells were cultured and treated with 10 nM of 1α,25(OH)2D3 (1,25D) or TX 527 or vehicle (0.01% ethanol) for 48 h LC3 and Tubulin levels
were evaluated by Western blot. A representative blot of three independent experiments is shown, and the quantification is represented in bar graphs. Full, non-
adjusted and uncropped images are shown in suppl. Material. In A) significant differences between conditions were evaluated by Student's t test between 1,25D or
TX 527 or CQ and ctrl (*p < 0.05, **p < 0.01) whereas in B) significant differences between control (vehicle) and agonists were analyzed by one-way ANOVA,
followed by the Bonferroni test. Significant differences between conditions are indicated by different letters (p < 0.05).
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